MUC1 and ovarian carcinoma: In a phase 1/2 clinical trial, anti-MUC1 CAR NK cells were derived from a NK-92 cell line to treat lung, pancreatic, colon, and ovarian cancers, with a specific focus on tumors co-expressing PD-L1 and MUC1 (NCT02839954).